It looks like you're new here. If you want to get involved, click one of these buttons!
ARK is already a big owner of some small stocks. At Israeli biotech company Pluristem Therapeutics Inc., with a total stock-market value of $219 million, ARK holds 15.5% of the shares outstanding. That’s three times as much as all other institutional owners combined. At a French biotech, Cellectis S.A. , with a $900 million market value, ARK owns 11.5%—more than the next 11 largest holders combined.Although those two positions make up barely 0.5% of ARK’s total assets, they reflect the firm’s style.
© 2015 Mutual Fund Observer. All rights reserved.